This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vaxart Gets New CEO, Focuses on Coronavirus Vaccine Program
by Zacks Equity Research
Vaxart (VXRT) management names Andrei Floroiu as its next chief executive officer with immediate effect. Stock appreciates on this news.
Emergent (EBS) to Manufacture AstraZeneca's Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions (EBS) inks a deal with AstraZeneca to provide its CDMO services for supporting the manufacturing of the latter's COVID-19 vaccine candidate, AZD1222.
Is Emergent BioSolutions (EBS) Stock a Solid Choice Right Now?
by Zacks Equity Research
Emergent BioSolutions (EBS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Is Emergent Biosolutions (EBS) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.
Emergent Biosolutions (EBS) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Emergent Biosolutions (EBS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks For June 11th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Emergent (EBS) Down on Unfavorable Patent Ruling on Narcan
by Zacks Equity Research
Emergent's (EBS) stock falls after a district court rules against the patent litigation on its Narcan nasal spray product. The court ruled in favor of Teva Pharmaceuticals, the defendants.
Novavax Clinches $60M Defense Contract for Coronavirus Vaccine
by Zacks Equity Research
Novavax (NVAX) secures a $60-million pact from the US Department of Defense to manufacture its COVID-19 vaccine candidate, NVX-CoV2373.
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Emergent Biosolutions (EBS) Up 12.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novavax Begins Clinical Study for Coronavirus Vaccine
by Zacks.com
Novavax (NVAX) enrolls the first set of participants in a phase I/II clinical study for evaluating its coronavirus vaccine candidate, NVX-CoV2373.
Novovax (NVAX) Surges on CEPI Funding for Coronavirus Vaccine
by Zacks Equity Research
Novovax (NVAX) is set to receive funding of up to $388 million from CEPI to support clinical development and scaling up of production of its coronavirus vaccine candidate.
Novavax Soars on Coronavirus Vaccine Funding: ETFs to Gain
by Sweta Jaiswal, FRM
Novavax received funding for the coronavirus vaccine and also delivered better-than-expected Q1 results resulting in a stock rally in yesterday's trading session.
Emergent (EBS) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Emergent's (EBS) earnings and revenues surpass estimates in the first quarter of 2020. The company reaffirms its guidance for the ongoing year.
Emergent Biosolutions (EBS) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 150.00% and 1.28%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Vaxart (VXRT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
During Vaxart's (VXRT) upcoming Q1 earnings call, investor focus will be on the company's progress with its oral vaccine candidates against SARS CoV-2.
Will Emergent Biosolutions (EBS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vaxart Up on Pre-Clinical Data on Coronavirus Vaccine Candidates
by Zacks Equity Research
Vaxart's (VXRT) several COVID-19 vaccine candidates generate immune responses in pre-clinical studies. Stock rises.
Novovax Up on Rapid Progress of Coronavirus Vaccine Candidate
by Zacks Equity Research
Novovax (NVAX) announces plans to initiate clinical study to evaluate its coronavirus vaccine candidate in May, weeks ahead of schedule.
4 Stocks Trading Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development
by Sweta Jaiswal, FRM
The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
Top Sectors of Q1 & Their Winning Stocks
by Sanghamitra Saha
Inside the top-performing sectors of Q1 and their winning stocks.
Why Is Emergent Biosolutions (EBS) Down 23.6% Since Last Earnings Report?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IMV to Develop Vaccine Candidate Against COVID-19, Shares Up
by Zacks Equity Research
IMV plans to develop a vaccine candidate using its lipid-based delivery platform, DPX technology, for the treatment of coronavirus disease. Stock rises.
Emergent (EBS) to Help Vaxart Develop Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions (EBS) teams up with Vaxart to support development of the latter's oral vaccine candidate for treating coronavirus disease.